

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HAENSLER *et al.*

Appl. No. 08/836,576

U.S. Natl. Phase of PCT/FR95/01495

Intl. Appl. Filed: November 14, 1995

102(e) Date: September 9, 1997

For: **Adjuvant for Vaccine Composition**

Art Unit: 1643

Examiner: Brumback, B.

Atty. Docket: 0725.0100001/MAC/GER

Second Supplemental Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

The numbering on the Second Supplemental Information Disclosure Statement is a continuation of the numbering in the Applicants' First Supplemental Information Disclosure Statement, filed March 4, 1998.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 are based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not

06/10/1999 PHILSON

00000005 0083576

01 FC:126

240100-00

exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Attached is our Check No. 24606 in the amount of \$240 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Grant E. Reed
Agent for Applicants
Registration No. 41,264

Date: June 9, 1999

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\AMYC\0725\0100001\pldg 0725 0100001
SKGF Rev. 5/29/98